The Safety of Nafamostat Mesylate for Patients With High Risk Bleeding Undergoing Hemodialysis: A Pilot Study

Wonju Severance Christian Hospital

Status: Enrolling

Conditions: Dialysis; Complications; Bleeding

Treatments: Drug: Nafamostat Mesylate

Study type: Interventional

Funder types: Other

Identifiers

NCT05874674

CR122018

Details and patient eligibility

About

Comparison nafamostat and low molecular weight heparin among dialysis patients

Enrollment: 100 estimated patients

Sex: All

Ages: 18 to 99 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• platelet below 10k PTT above 60 second INR above 20 patient with bleeding (epistaxis, orbital bleeding, hematuria) recent brain hemorrhage (within 6 months) receiving anticoagulant therapy (coumadin or NOAC) dual antiplatelet agent users received major surgery within one month

Exclusion criteria

• cancer liver cirrhosis pregnancy drug allergy current bleeding on major organ (brain, gastrointestinal)

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

100 participants in 2 patient groups

nafamostat

Active Comparator group

Description:

Patients received dialysis through nafamostat

Treatment:

Drug: Nafamostat Mesylate

Cnoxane

No Intervention group

Description:

Patients received dialysis through cnoxan